Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer

Autor: Giuseppe Giaccone, Clemens M F Dirven, J.C.A. Baayen, C.J. van Groeningen, K. van der Born, G.J. Peters, J. Sigmond, S.M. de Lange, Richard J. Honeywell, Tjeerd J. Postma, Andre M. Bergman, A.C. Laan

Publikováno v: Sigmond, J, Honeywell, R J, Postma, T J, Dirven, C M, de Lange, S M, van der Born, K, Laan, A, Baayen, J C, van Groeningen, C J, Bergman, A M, Giaccone, G & Peters, G J 2009, ' Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer ', Annals of Oncology, vol. 20, no. 1, pp. 182-187 . https://doi.org/10.1093/annonc/mdn543
Annals of Oncology, 20(1), 182-187. Elsevier Ltd.
Annals of Oncology, 20(1), 182-187. Oxford University Press

Glioblastoma multiforme (GBM), the most frequent malignant brain tumor, has a poor prognosis, but is relatively sensitive to radiation. Both gemcitabine and its metabolite difluorodeoxyuridine (dFdU) are potent radiosensitizers. The aim of this phase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36b798c2a7b9ecb35945758e6851be2e
https://doi.org/10.1093/annonc/mdn543